Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-301 in dry age-related macular degeneration with geographic atrophy
NCT05170048Phase 2Not yet recruiting
- Sponsor
- Evergreen Therapeutics, Inc.
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of EG-301 in age-related macular degeneration (AMD) (2 arms), sponsored by Evergreen Therapeutics, Inc. Primary endpoints: Adverse Events at 30 weeks, Geographic Atrophy Lesion Size Change at 26 weeks and 6 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
EG-301
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT05170048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170048.